471 related articles for article (PubMed ID: 16377677)
1. Posaconazole as salvage therapy for zygomycosis.
Greenberg RN; Mullane K; van Burik JA; Raad I; Abzug MJ; Anstead G; Herbrecht R; Langston A; Marr KA; Schiller G; Schuster M; Wingard JR; Gonzalez CE; Revankar SG; Corcoran G; Kryscio RJ; Hare R
Antimicrob Agents Chemother; 2006 Jan; 50(1):126-33. PubMed ID: 16377677
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis.
Egelund EF; Egelund TA; Ng JS; Wassil SK; Peloquin CA
Pharmacotherapy; 2013 Jan; 33(1):e1-8. PubMed ID: 23307552
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole.
Keating GM
Drugs; 2005; 65(11):1553-67; discussion 1568-9. PubMed ID: 16033292
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature.
Page RL; Schwiesow J; Hilts A
Pharmacotherapy; 2007 Feb; 27(2):290-8. PubMed ID: 17253919
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.
van Burik JA; Hare RS; Solomon HF; Corrado ML; Kontoyiannis DP
Clin Infect Dis; 2006 Apr; 42(7):e61-5. PubMed ID: 16511748
[TBL] [Abstract][Full Text] [Related]
6. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
7. Current experience in treating invasive zygomycosis with posaconazole.
Cornely OA; Vehreschild JJ; Rüping MJ
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():77-81. PubMed ID: 19754763
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole: a new broad-spectrum antifungal agent.
Kwon DS; Mylonakis E
Expert Opin Pharmacother; 2007 Jun; 8(8):1167-78. PubMed ID: 17516880
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
Spreghini E; Orlando F; Giannini D; Barchiesi F
J Antimicrob Chemother; 2010 Oct; 65(10):2158-63. PubMed ID: 20667887
[TBL] [Abstract][Full Text] [Related]
10. Zygomycosis over-infection during voriconazole therapy for aspergillosis in a heart transplant patient, successfully treated with liposomal amphotericin and posaconazole.
Bourke P; Castro P; Rabagliati R; Beltran C; Verdejo H; Winter JL; Bourge RC
Transpl Infect Dis; 2012 Oct; 14(5):E56-9. PubMed ID: 22852999
[TBL] [Abstract][Full Text] [Related]
11. Activity of posaconazole in treatment of experimental disseminated zygomycosis.
Dannaoui E; Meis JF; Loebenberg D; Verweij PE
Antimicrob Agents Chemother; 2003 Nov; 47(11):3647-50. PubMed ID: 14576138
[TBL] [Abstract][Full Text] [Related]
12. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.
Herbrecht R
Int J Clin Pract; 2004 Jun; 58(6):612-24. PubMed ID: 15311563
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
Krishna G; Sansone-Parsons A; Martinho M; Kantesaria B; Pedicone L
Antimicrob Agents Chemother; 2007 Mar; 51(3):812-8. PubMed ID: 17210771
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
[TBL] [Abstract][Full Text] [Related]
15. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.
Skiest DJ; Vazquez JA; Anstead GM; Graybill JR; Reynes J; Ward D; Hare R; Boparai N; Isaacs R
Clin Infect Dis; 2007 Feb; 44(4):607-14. PubMed ID: 17243069
[TBL] [Abstract][Full Text] [Related]
16. Posaconazole: a broad-spectrum triazole antifungal.
Torres HA; Hachem RY; Chemaly RF; Kontoyiannis DP; Raad II
Lancet Infect Dis; 2005 Dec; 5(12):775-85. PubMed ID: 16310149
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.
Heinz WJ; Egerer G; Lellek H; Boehme A; Greiner J
Mycoses; 2013 May; 56(3):304-10. PubMed ID: 23170837
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
Ibrahim AS; Gebremariam T; Schwartz JA; Edwards JE; Spellberg B
Antimicrob Agents Chemother; 2009 Feb; 53(2):772-5. PubMed ID: 18936190
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
Winston DJ; Bartoni K; Territo MC; Schiller GJ
Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
